BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11285159)

  • 41. Dethroning AZT.
    Gilden D; Falkenberg J; Torres G
    GMHC Treat Issues; 1997 Feb; 11(2):10-3. PubMed ID: 11364106
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
    Havlir DV; Gilbert PB; Bennett K; Collier AC; Hirsch MS; Tebas P; Adams EM; Wheat LJ; Goodwin D; Schnittman S; Holohan MK; Richman DD;
    AIDS; 2001 Jul; 15(11):1379-88. PubMed ID: 11504959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients.
    de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J
    J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
    Zala C; Salomón H; Cahn P
    Antivir Ther; 1999; 4 Suppl 3():95-9. PubMed ID: 16021880
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients.
    Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher HC; Bernasconi E; Sudre P; Leduc D; Yerly S; Perrin LH; Hirschel B
    AIDS; 1998 May; 12(8):F71-7. PubMed ID: 9631134
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
    Fisher M
    AIDS; 1998; 12 Suppl 3():S9-16. PubMed ID: 15168718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
    Lori F; Jessen H; Lieberman J; Clerici M; Tinelli C; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 May; 15(7):619-24. PubMed ID: 10331440
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
    Lowe SH; van Leeuwen E; Droste JA; van der Veen F; Reiss P; Lange JM; Burger DM; Repping S; Prins JM
    Ther Drug Monit; 2007 Oct; 29(5):566-70. PubMed ID: 17898645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is Hydroxyurea for real?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.
    Kline MW; Calles NR; Simon C; Schwarzwald H
    Pediatr Infect Dis J; 2000 Nov; 19(11):1083-6. PubMed ID: 11099091
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir.
    Lori F; Jessen H; Lieberman J; Finzi D; Rosenberg E; Tinelli C; Walker B; Siliciano RF; Lisziewicz J
    J Infect Dis; 1999 Dec; 180(6):1827-32. PubMed ID: 10558937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term suppression of HIV-1 by hydroxyurea and didanosine.
    Lori F; Jessen H; Foli A; Lisziewicz J; Matteo PS
    JAMA; 1997 May; 277(18):1437-8. PubMed ID: 9145714
    [No Abstract]   [Full Text] [Related]  

  • 56. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
    Luzuriaga K; Bryson Y; Krogstad P; Robinson J; Stechenberg B; Lamson M; Cort S; Sullivan JL
    N Engl J Med; 1997 May; 336(19):1343-9. PubMed ID: 9134874
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
    Lori F; Malykh AG; Foli A; Maserati R; De Antoni A; Minoli L; Padrini D; Degli Antoni A; Barchi E; Jessen H; Wainberg MA; Gallo RC; Lisziewicz J
    AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1403-9. PubMed ID: 9359660
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy.
    Barreiro P; de Mendoza C; Soriano V; González-Lahoz J
    AIDS; 2000 Jan; 14(2):207-8. PubMed ID: 10708295
    [No Abstract]   [Full Text] [Related]  

  • 59. Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
    AIDS Treat News; 1999 Dec; (No 332):8. PubMed ID: 11367131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.